Atlas Trials

A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients

Clinical trial NCT00752518 · COMPLETED

Trial details

NCT number
NCT00752518
Sponsor
Janssen Pharmaceutical K.K.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
RefractoryMultiple MyelomaRelapse
Start date
2004-05-01
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.